Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA
Status:
Completed
Trial end date:
2019-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of Olmutinib(Olita®) in patients with
T790M-positive non-small cell lung cancer (NSCLC) confirmed using DNA extracted from
extracellular vesicles of bronchoalveolar lavage fluid.